The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China
The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China
复制标题
DOI：
10.1186/s13613-020-00653-z
复制
发表时间：
2020-03-30
影响因子：
8.1
通讯作者：
Duan, Jun
中科院分区：
文献类型：
--
作者：
Wang, Ke;Zhao, Wei;Duan, Jun
背景 目前，新型冠状病毒（2019-nCoV）感染的肺炎（NCIP）正在中国暴发。大多数危重患者接受了高流量鼻导管（HFNC）氧疗。然而，HFNC 在这一人群中的应用经验还很缺乏。方法 回顾性筛查2020年1月1日至3月4日在中国重庆市两家医院确诊的318例NCIP患者。其中27例（8.4%）患者出现严重急性呼吸衰竭，其中17例（63%）接受HFNC一线治疗，9例（33%）接受无创通气（NIV）治疗，1例（4%）接受有创通气治疗。 HFNC 失败的定义是需要 NIV 或插管作为救援治疗。结果 17 名 HFNC 患者中，7 名（41%）经历了 HFNC 失败。 PaO2/FiO(2) > 200 mm Hg 的患者的 HFNC 失败率为 0% (0/6)，而 PaO2/FiO(2) 的患者的 HFNC 失败率为 63% (7/11)
Background The outbreak of a novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) is currently ongoing in China. Most of the critically ill patients received high-flow nasal cannula (HFNC) oxygen therapy. However, the experience of HFNC in this population is lacking. Methods We retrospectively screened 318 confirmed patients with NCIP in two hospitals of Chongqing, China, from January 1st to March 4th, 2020. Among them, 27 (8.4%) patients experienced severe acute respiratory failure including 17 patients (63%) treated with HFNC as first-line therapy, 9 patients (33%) treated with noninvasive ventilation (NIV) and one patient (4%) treated with invasive ventilation. HFNC failure was defined by the need of NIV or intubation as rescue therapy. Results Of the 17 HFNC patients, 7 (41%) experienced HFNC failure. The HFNC failure rate was 0% (0/6) in patients with PaO2/FiO(2) > 200 mm Hg vs. 63% (7/11) in those with PaO2/FiO(2)